Gynecologic Cancer

Ovarian Cancer Maintenance: PRIMA, PAOLA-1, VELIA, and Others
Michael Birrer, MD, PhD, director of the Winthrop P Rockefeller Cancer Institute, University of Arkansas for Medical…
SCCA Launches Project for Patient-Centered Education, Support for Women With Advanced Ovarian Cancer
Barbara Goff, MD, Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses a project she is…
Maintenance vs Surgery Plus Chemo for Upfront Ovarian Cancer Treatment
Thomas Krivak, MD, Allegheny Health Network, explains the "two schools of thought" for physicians treating…
Niraparib as Frontline Option for High-Risk Ovarian Cancer
Thomas Krivak, MD, Allegheny Health Network, gives a quick summary of a clinical trial that assessed niraparib in the…
Importance of the PRIMA Study in the Context of Ovarian Cancer Treatment
Alexander Olawaiye, MD, contextualizes the results of the PRIMA study and the support for PARP inhibitors in the…
PARP Inhibitor After First-Line Chemo as Standard Care for Newly-Diagnosed Advanced Ovarian Cancer
Antonio Gonzalez-Martin, MD, discusses the PRIMA study of niraparib in patients with newly-diagnosed ovarian cancer.
Decline of a "Gold-Standard" Treatment in Cervical Cancer
Timothy Showalter, MD, discusses why brachytherapy is being used less and less for the treatment of cervical cancer and…
Back to Top